Regulatory challenges
Delays in market access
- Materiality
- high
Oncopeptides
Oncopeptides is a Swedish biopharmaceutical company focused on developing and commercializing therapies for difficult-to-treat hematological diseases. The company is known for its proprietary Peptide-Drug Conjugate (PDC) platform, which has shown promise in treating multiple myeloma and is being expanded to other indications such as glioblastoma. Oncopeptides has achieved significant market access in Europe, particularly in Italy and Spain, and is actively pursuing opportunities in Japan. The company's flagship product, Pepaxti, has driven substantial sales growth, reflecting its strong demand in key markets.
75
2.63
2.45
| % | |
|---|---|
| Pharmaceuticals | 70% Includes Pepaxti and other drug products |
| Research and Development | 20% Focuses on PDC platform and new indications |
| Market Access Services | 10% Facilitates drug approval and commercialization |
Oncopeptides primarily serves healthcare providers and institutions specializing in hematology and oncology...
- Healthcare Providersprimary
Purchase Pepaxti for treating multiple myeloma
- Pharmaceutical Partnerssecondary
Engage in licensing and distribution agreements
- Research Institutionsemerging
Collaborate on PDC platform development
Oncopeptides is headquartered in Stockholm, Sweden, and has a significant presence in the European market, particularly...
- •Headquartered in Stockholm, Sweden
- •Strong market presence in Italy and Spain
- •Advanced negotiations for market entry in Japan
- •Subsidiaries in Germany and other European countries
- •Strategic expansion into Asian markets
Oncopeptides is focused on expanding its Peptide-Drug Conjugate (PDC) platform to address new indications beyond...
01
Expand PDC platformmedium-term
To address new high-value indications
02
Achieve positive cash flowlong-term
To ensure financial sustainability
03
Market accessshort-term
To increase sales and market presence
Oncopeptides faces several risks, including regulatory challenges in securing market access for its products in new...
Geopolitical risks
Impact on healthcare policies
- Materiality
- high
Demand fluctuations
Affects revenue stability
- Materiality
- medium
Revenue recognition timing
Cash flow management
Estimates and provisions
Swedish Orphan Biovitrum
SOBI.ST · Health Care
Swedish Orphan Biovitrum AB (Sobi) is a global biopharmaceutical company dedicated to transforming the lives of individuals with rare and debilitating diseases.
Orion Oyj
ORNBV.HE · Drug Manufacturers - General
Orion is a Finnish pharmaceutical company that operates globally, focusing on the development, manufacturing, and marketing of human and animal medicines, as…
Cantargia
CANTA.ST · Health Care
Cantargia is a Swedish biotechnology company focused on developing targeted antibody-based drugs for cancer, immunological, and other life-threatening diseases.
BICYCLE THERAPEUTICS PLC
BCYC · Pharmaceutical Preparations
Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company built around its proprietary Bicycle platform, which is used to design short synthetic…
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
PepGen Inc.
PEPG · Pharmaceutical Preparations
: 11/08/2026